TECHNOLOGY & PRODUCTS

Intellectual Property

Patents

GeoVax is aggressively pursuing a strong patent position on the proprietary technology developed in our collaboration between Emory University, the NIH, and the CDC. Patent applications are being filed with the USA Patent and Trademark Office and in specific international markets (countries).

Patent applications include provisions to cover our DNA and MVA based AIDS vaccines, their multi-protein components, composition, structure, claim of immunization against multiple subtypes of HIV, routes of administration, safety and other related factors. Patent claims filed for our vaccines include provisions for protection against two diseases: HIV/AIDS and smallpox.

GeoVax has a major Patent Portfolio protecting our AIDS vaccine technology with:

• 5 Issued Patents controlling the AIDS vaccine manufacturing process (exclusive rights).
• 12 Filed Patents in the USA and several other key countries on various components and compositions of our AIDS vaccine (exclusive rights).
• 4 Approved Patents licensed from the NIH related to the ability of our MVA vector vaccine as a vehicle to deliver HIV virus antigens, and also to induce an immune response in humans. These are key licensed patents for the use of MVA as a method for delivering our HIV-1 antigens as an AIDS vaccine.